Cassava Sciences: Operational outlook following DOJ investigation dismissal and SEC settlement Feb 2026

Federal Scrutiny Ends: DOJ Closes Cassava Sciences File

The Department of Justice has formally closed its investigation into Cassava Sciences, marking the end of a five-year legal siege that paralleled the collapse of the company’s lead Alzheimer’s candidate, simufilam. The decision to decline criminal charges against the corporate entity in February 2026 follows the high-profile dismissal of fraud charges against the company’s longtime scientific collaborator, Dr. Hoau-Yan Wang, in October 2025. This regulatory ceasefire leaves Cassava Sciences legally cleared operationally hollowed, having paid over $40 million in civil penalties while its primary asset failed two Phase 3 clinical trials in late 2024 and early 2025.

The Wang Indictment Collapse (October 2025)

The catalyst for the DOJ’s retreat was the collapse of its case against Dr. Hoau-Yan Wang, the City University of New York (CUNY) professor whose research underpinned simufilam. On October 23, 2025, Judge Theodore Chuang of the U. S. District Court for the District of Maryland granted the DOJ’s motion to dismiss the indictment “with prejudice,” preventing the charges from being refiled. The dismissal came after the defense successfully challenged the reliability of the prosecution’s primary expert witness, Dr. Paul Brookes.

Court filings from late 2025 reveal that the prosecution’s case relied heavily on a “bespoke method” of image analysis to prove data manipulation in Western blots. The defense argued this method had not gained general acceptance in the scientific community, failing the Daubert standard for admissible evidence. Facing the prospect of their key testimony being excluded, federal prosecutors moved to drop the charges, citing the “interests of justice.” This legal failure significantly weakened any chance criminal theory against Cassava Sciences itself, as the alleged fraud originated with Wang’s academic data.

SEC Settlement and Civil Penalties (September 2024)

While the criminal case dissolved, Cassava Sciences faced substantial liability on the civil front. On September 26, 2024, the U. S. Securities and Exchange Commission (SEC) announced a settlement with the company, former CEO Remi Barbier, and former Senior Vice President Dr. Lindsay Burns. The agency charged the defendants with “negligence-based disclosure” violations rather than intentional fraud, a distinction that allowed the company to survive imposed heavy financial and reputational costs.

The SEC investigation found that Cassava misled investors by claiming its Phase 2b bioanalyses were conducted under blinded conditions. In reality, Dr. Wang had been provided with unblinded data, allowing him to identify approximately one-third of the patients. This breach compromised the integrity of the data used to raise over $260 million in capital. Under the settlement terms, Cassava Sciences paid a $40 million civil penalty. Remi Barbier paid $175, 000 and agreed to a three-year officer-and-director bar. Dr. Lindsay Burns paid $85, 000 and accepted a five-year bar.

Regulatory and Clinical Timeline (2020, 2025)

The convergence of clinical failures and regulatory actions created a destructive feedback loop for the company between 2024 and 2025. The following table outlines the key events leading to the current case closure.

Executive Overhaul and Operational Contraction

The regulatory pressure forced a complete leadership change prior to the case closure. Following the SEC charges, Richard (Rick) Barry took over as Executive Chairman and later CEO. His tenure has been defined by emergency management and liquidation of the Alzheimer’s program. In March 2025, following the failure of the second Phase 3 trial (REFOCUS-ALZ), Barry announced the company would “discontinue all efforts” for simufilam in Alzheimer’s disease. The company shifted focus to a smaller indication for tuberous sclerosis complex (TSC), the FDA placed a clinical hold on this program in late 2025, demanding further pre-clinical data.

“We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit… These results were unambiguous.” , Rick Barry, CEO (March 25, 2025).

The dismissal of the DOJ investigation removes the threat of a corporate criminal indictment, which could have forced an immediate liquidation. Yet, the victory is pyrrhic. The company spent years and millions defending the integrity of data that failed to translate into clinical efficacy. The $40 million SEC penalty absorbed of the company’s remaining cash, which stood at approximately $117-$127 million at the end of 2024. By the time the DOJ file was closed in early 2026, Cassava Sciences had morphed from a $5 billion biotech contender into a cash-constrained shell with no late-stage pipeline.

Federal Securities Resolution: The $40 Million Accord

On September 26, 2024, the U. S. Securities and Exchange Commission (SEC) executed a definitive settlement with Cassava Sciences, imposing a $40 million civil penalty to resolve charges of negligence-based disclosure violations. The agreement concluded a multi-year investigation into the company’s communications regarding its Phase 2b clinical trial for simufilam. While Cassava Sciences neither admitted nor denied the SEC’s findings, the financial sanction represented a significant liquidity event, directly reducing the company’s cash reserves which stood at approximately $149 million at the close of Q3 2024.

The settlement structure extended liability beyond the corporate entity to its former top leadership. Remi Barbier, the company’s founder and former CEO, agreed to a $175, 000 penalty and a three-year officer-and-director bar. Dr. Lindsay Burns, the former Senior Vice President of Neuroscience, consented to an $85, 000 penalty and a five-year bar from serving as an officer or director of a public company. These individual sanctions underscored the SEC’s focus on executive accountability regarding the integrity of clinical data disclosures.

Anatomy of the Disclosure Violations

The SEC’s complaint centered on the company’s claims that its Phase 2b bioanalysis was conducted under “blinded” conditions. Federal investigators determined that Dr. Hoau-Yan Wang, a co-developer of simufilam and researcher at the City University of New York (CUNY), had been provided with unblinding information prior to his analysis. This data allowed Wang to identify approximately one-third of the trial participants, compromising the scientific integrity of the reported results.

also, the Commission found that the company misled investors by announcing “significant improvements” in patient cognition based on a subset of data hand-selected by Dr. Burns. The full dataset, which included all patients, showed no measurable cognitive improvement in episodic memory. This gap between the full dataset and the cherry-picked results formed the basis of the charges under Section 17(a)(2) and (3) of the Securities Act of 1933, provisions that address negligent conduct in the offer or sale of securities.

Operational Compliance and Governance Reforms

Following the settlement, Cassava Sciences implemented a series of remedial measures mandated to prevent future disclosure failures. These reforms included the restructuring of its Board of Directors and the installation of new executive leadership. Richard Barry, initially appointed as Executive Chairman in July 2024, assumed the role of CEO to steer the company through the compliance overhaul. The company also established stricter internal controls over the verification of scientific data before public release, a direct response to the breakdown in oversight concerning Dr. Wang’s laboratory practices.

Financial Impact and Cash Position

The $40 million penalty was paid from existing cash on hand, a move that tightened the company’s operational runway as it method the readout of its Phase 3 trials. even with this outlay, Cassava maintained a debt-free balance sheet through the end of 2024, with year-end cash reserves estimated between $117 million and $127 million. The settlement cleared the regulatory overhang from the SEC, allowing the company to proceed without the threat of continued civil litigation from the agency, although it did not insulate the firm from the subsequent operational pivot necessitated by the Phase 3 trial outcomes in late 2025.

“The investigation found that Cassava and its senior executives negligently misled investors by claiming that the Phase 2b trial was conducted under blinded conditions, when in fact, the data had been unblinded to the researcher analyzing the samples.” , SEC Division of Enforcement, September 2024.

Simufilam AD Program Termination: RETHINK & REFOCUS Autopsy

The definitive collapse of Cassava Sciences’ Alzheimer’s disease (AD) program occurred in two distinct phases between late 2024 and early 2025, the clinical hypothesis that had sustained the company’s valuation for years. The termination of the simufilam program was not a regulatory halt a scientific failure, confirmed by data from two Phase 3 trials, RETHINK-ALZ and REFOCUS-ALZ. These studies, designed to validate the efficacy of simufilam in mild-to-moderate AD, failed to meet their co-primary endpoints, leading to a complete cessation of development by the second quarter of 2025.

Phase 3 Clinical Failure Timeline

The blow arrived on November 25, 2024, when Cassava released topline results from the 52-week RETHINK-ALZ trial (NCT04994483). The study, which randomized 804 patients, missed both its primary cognitive and functional endpoints. The immediate was severe: the company’s stock value eroded by approximately 85% in a single trading session, and management announced the immediate discontinuation of the open-label extension study.

The final confirmation came four months later. On March 25, 2025, Cassava reported topline data from the larger, 76-week REFOCUS-ALZ trial (NCT05026177). even with a longer treatment duration and a larger cohort of 1, 125 patients, the drug demonstrated no statistically significant benefit over placebo. In a decisive move, CEO Rick Barry, who had taken the helm following the executive shakeup in July 2024, declared the results “unambiguous” and initiated the complete phase-out of the AD program.

Data Autopsy: The REFOCUS-ALZ Metrics

The failure of REFOCUS-ALZ was absolute across all key metrics. The trial measured efficacy using the Alzheimer’s Disease Assessment -Cognitive Subscale (ADAS-Cog12) and the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL). Verified data released in March 2025 showed that patients on simufilam performed numerically worse than those on placebo in several measures.

The data revealed that the placebo group experienced less cognitive decline (+4. 70 points) than either treatment arm (+4. 97 and +5. 26 points). This inversion of the expected therapeutic effect nullified the drug’s method of action hypothesis. also, the safety profile, while favorable, became irrelevant in the absence of efficacy.

Post-Mortem Publication and Biomarker problem

On January 13, 2026, Cassava Sciences formalized these failures in the scientific record with a peer-reviewed publication in the Journal of Prevention of Alzheimer’s Disease (JPAD). The article provided a granular analysis of the failed trials and highlighted a serious operational flaw: diagnostic precision. An amyloid PET sub-study within REFOCUS-ALZ revealed that 21% of participants (33 of 160) were amyloid-negative at baseline. over one-fifth of the study population did not have Alzheimer’s pathology, a confounding factor that, while not solely responsible for the failure, underscored the difficulties in the trial’s execution.

“We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s disease. These results were unambiguous.” , Rick Barry, CEO, March 25, 2025.

Operational Restructuring and Pivot

Following the March 2025 data release, Cassava executed a rapid restructuring plan to preserve capital. The company implemented a workforce reduction of approximately 33% in the quarter of 2025. By the end of 2024, prior to the final REFOCUS read-out, the company held $128. 6 million in cash and cash equivalents. This capital reserve became the lifeline for the company’s pivot away from Alzheimer’s disease.

With the simufilam AD program terminated, Cassava redirected its remaining resources toward preclinical studies for Tuberous Sclerosis Complex (TSC)-related epilepsy. This strategic shift marked the end of the simufilam era, transitioning the company from a late-stage Phase 3 contender back to a preclinical entity, resetting its development timeline by a decade.

Q1 2026 Cash Position: Liquidity Analysis Post-Trial

Following the formal closure of the Department of Justice investigation in February 2026, Cassava Sciences (SAVA) enters the quarter with a balance sheet radically altered by regulatory penalties and the termination of its Alzheimer’s disease program. As of March 1, 2026, the company’s estimated unencumbered cash position stands between $58 million and $62 million. This figure represents a roughly 57% contraction in liquidity from the $149 million reported in September 2024, a decline driven primarily by the $40 million SEC civil penalty and a $31. 25 million provision for securities class action settlements recorded in mid-2025.

Cash Flow: The Settlement Drain (2024, 2026)

The of Cassava’s treasury was not driven by R&D investment, by the financial mechanics of legal resolution and clinical failure. Between Q4 2024 and Q4 2025, the company ceased its cash-intensive Phase 3 trials (ReThink and ReFocus) simultaneously incurred massive one-time outflows to resolve federal and civil allegations. The following liquidity isolates these non-operational expenditures against the company’s shrinking capital base.

Operational Burn Rate: The “Shell” Structure

The termination of the simufilam Alzheimer’s program in 2025 fundamentally altered the company’s expense structure. During the height of the Phase 3 trials in 2023 and 2024, Cassava’s quarterly cash burn frequently exceeded $20 million. With the dismissal of contract research organizations (CROs) and a 33% workforce reduction executed in January 2025, the company’s quarterly operational burn has collapsed to approximately $2. 5 million to $3. 5 million.

This “shell” structure preserves capital reflects a company with no late-stage clinical assets. The pivot to Tuberous Sclerosis Complex (TSC) epilepsy remains in the preclinical or early Phase 1 stage, requiring minimal capital relative to the massive outlays of the failed Alzheimer’s studies. Consequently, the current cash pile of ~$60 million provides a theoretical runway extending into 2028, assuming no new legal liabilities emerge. This extended runway is not a sign of health, of inactivity; the company is a holding entity for a small cash balance and early-stage intellectual property.

Analyst Note: The $31. 25 million loss contingency recorded in Q2 2025 for securities litigation ring-fenced a third of the company’s remaining capital. While the DOJ dismissal in February 2026 removes the threat of criminal asset forfeiture, the civil payouts have already converted shareholder equity into settlement checks.

Net Cash Valuation and Solvency

Investors in Q1 2026 are left valuing the company almost exclusively on a net-cash basis. With approximately 48 million shares outstanding, the estimated cash per share stands at roughly $1. 20 to $1. 30. The stock has traded near this book value since the ReFocus trial data release in March 2025 confirmed the drug’s failure. The resolution of the DOJ investigation removes a “zero-bound” risk, where legal fees or criminal fines could have forced bankruptcy, it does not restore value to the equity.

The company’s solvency is tied to its ability to manage the remaining treasury against the low-cost demands of the TSC program. There are no immediate liquidity crises on the horizon, as the $40 million SEC penalty and the bulk of the class action settlements have been accounted for. The primary financial risk has shifted from insolvency to attrition, where the remaining cash is slowly consumed by executive compensation and administrative overhead without a viable product to replenish the balance sheet.

Operational Burn Rate: Post-Restructuring Metrics

Following the termination of the Simufilam Alzheimer’s disease (AD) program and the execution of significant workforce reductions in early 2025, Cassava Sciences (SAVA) has entered a period of radical fiscal contraction. The company’s operational burn rate has decelerated sharply from its 2024 peak, reflecting a transition from late-stage clinical development to a preclinical and early-stage holding pattern. As of February 28, 2026, the company’s liquidity profile is defined by the preservation of capital against pending class-action liabilities rather than aggressive R&D deployment.

Cash Position and Liquidity Analysis (Q1 2026)

Cassava Sciences closed the fiscal year 2025 with an estimated cash and cash equivalents balance between $92 million and $96 million, a figure consistent with guidance provided in the Q3 2025 financial report. This represents a stabilized position following the payment of the $40 million SEC civil penalty in late 2024, which was escrowed in Q3 2024 and subsequently disbursed. The company remains debt-free, a serious factor in its ability to navigate the current “strategic hibernation” phase.

yet, the unencumbered cash position is threatened by the $31. 25 million securities class action settlement agreed to in January 2026. While this settlement resolves the consolidated claims from purchasers between September 2020 and October 2023, it earmarks approximately 33% of the company’s remaining liquidity. Adjusted for this liability, Cassava’s operating capital for 2026 stands at approximately $60 million to $65 million.

Burn Rate Reduction: 2024 vs. 2025

The collapse of the RETHINK-ALZ and REFOCUS-ALZ trials precipitated a massive reduction in operational expenditures. In 2024, the company’s net cash used in operations reached $116. 9 million, driven by the high costs of maintaining over 175 clinical sites globally and patient enrollment activities. By contrast, the operational cash burn for the nine months of 2025 plummeted to $22. 5 million, with full-year 2025 cash use estimated at approximately $36. 5 million.

This 69% reduction in annual cash burn is directly attributable to the termination of the Phase 3 program and the subsequent workforce reduction of approximately 33% implemented in January 2025. The discontinuation of the open-label extension studies further eliminated the recurring costs associated with long-term patient monitoring and drug supply logistics.

R&D and G&A Expenditure Trends

Research and Development (R&D) expenses have contracted to near-dormant levels. In the third quarter of 2025, R&D spending fell to $4. 0 million, a 78% decrease from the $17. 7 million reported in the same period of 2024. The composition of R&D spending has shifted from clinical trial management (CRO fees, site payments) to data analysis and close-out costs. With the FDA placing a full clinical hold on the proposed Tuberous Sclerosis Complex (TSC) trial in January 2026, R&D burn is expected to remain suppressed throughout the half of 2026, comprised primarily of fixed personnel costs and regulatory maintenance.

General and Administrative (G&A) expenses have also declined, though less precipitously than R&D. Q3 2025 G&A expenses were $7. 9 million, down from $12. 9 million in Q3 2024. The persistence of elevated G&A costs relative to the company’s size is largely due to lingering legal fees associated with the DOJ and SEC resolutions, as well as the defense costs for the -settled class action lawsuit. With the DOJ investigation formally closed in February 2026, legal retainers are projected to drop significantly, chance bringing quarterly G&A spend $5 million by Q3 2026.

“The company estimates cash at year-end 2025 in a range from $92 to $96 million… This represents a downward revision from previous guidance for net cash use in operations for second half 2025.” , Cassava Sciences Q3 2025 Financial Report

Runway Projections Post-Settlement

Based on a projected quarterly burn rate of $8 million to $10 million (assuming minimal clinical activity and reduced legal fees), and an adjusted cash balance of ~$60 million post-settlement, Cassava Sciences possesses a financial runway extending into late 2027. This extended runway provides the Board with a window to evaluate strategic alternatives, including a chance reverse merger or liquidation, without the immediate pressure of insolvency. yet, the absence of a viable clinical asset following the TSC clinical hold renders this liquidity a wasting asset rather than a growth engine.

The “Lifeboat” Strategy: From Alzheimer’s to Orphan Disease

Following the catastrophic collapse of its Alzheimer’s disease (AD) program in 2025, Cassava Sciences has executed a radical strategic shift, channeling its remaining resources into a singular, high-risk clinical asset: Simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy. This pivot, initiated via a licensing agreement with Yale University in February 2025, represents the company’s final attempt to salvage value from the Simufilam molecule. The transition, yet, has been anything smooth. While the Department of Justice investigation closure in February 2026 removed a significant legal overhang, the operational reality is defined by a new regulatory blockade: a full FDA clinical hold imposed in December 2025.

The company’s survival hinges entirely on a hypothesis linking Filamin A (FLNA) modulation to the mTOR signaling pathway, a method distinct from the amyloid-beta theories that grounded its failed Alzheimer’s trials. With the AD program terminated and the workforce reduced by approximately 33% in early 2025, Cassava has reorganized as a single-asset, rare-disease biotech. The TSC indication a patient population of approximately 50, 000 in the United States, a fraction of the Alzheimer’s market, offers the chance for Orphan Drug Designation and a more focused clinical pathway.

Scientific Basis and Yale Licensing Deal

The scientific foundation for this pivot rests on research conducted by Dr. Angélique Bordey at Yale School of Medicine. On February 26, 2025, Cassava secured a worldwide license for the method of treatment patent based on Bordey’s work. The central premise is that mutations in TSC1 or TSC2 genes, which cause Tuberous Sclerosis Complex, lead to hyperactivity of the mTOR pathway and an aberrant increase in Filamin A levels. This overexpression of FLNA contributes to dendritic malformations and seizure activity.

Unlike the controversial method proposed for Alzheimer’s, the TSC hypothesis posits that Simufilam can normalize FLNA activity, so reducing seizure frequency in refractory patients. Approximately 80% to 90% of TSC patients experience seizures, with nearly two-thirds becoming resistant to standard antiepileptic drugs. The company is betting that Simufilam can address this unmet need where traditional mTOR inhibitors have shown mixed results.

“Dr. Bordey’s research opens the door to a chance new therapeutic application for simufilam in the treatment of seizures related to rare neurodevelopmental disorders… We plan to conduct preclinical studies in collaboration with the TSC Alliance.”
, Rick Barry, CEO of Cassava Sciences (February 28, 2025)

Preclinical Data and August 2025 Readout

In August 2025, Cassava released data from a preclinical study involving the Tsc1 conditional knockout (CKO) mouse model, a standard for testing TSC therapeutics. The study, conducted in collaboration with the TSC Alliance and PsychoGenics, Inc., reported that Simufilam attenuated seizure progression and demonstrated a dose-dependent reduction in seizure frequency. These results were serious in justifying the continued expenditure on Simufilam after the AD program’s failure in March 2025.

The data indicated a statistically significant correlation between dosage and seizure reduction, providing the independent validation of the drug’s effect in a non-AD model. yet, the study also noted that “not all parameters measured reached statistical significance,” a detail that foreshadowed the regulatory scrutiny to come. even with this, the company aggressively positioned the data as a green light for human trials, targeting a Phase 2 proof-of-concept study launch in the half of 2026.

Regulatory Blockade: The December 2025 Clinical Hold

The company’s timeline faced a severe collision with regulatory reality on December 18, 2025. The FDA issued a full clinical hold on the proposed Investigational New Drug (IND) application for the TSC proof-of-concept trial. This intervention halted all clinical activities before they could begin, forcing Cassava to miss its H1 2026 initiation target.

According to SEC filings, the FDA requested additional preclinical data and specific modifications to the trial protocol to assess chance risks to human subjects. This hold is not a procedural delay; it reflects a heightened level of regulatory caution surrounding Simufilam following the high-profile failure and controversy of the Alzheimer’s program. The requirement for “more pre-clinical data” implies that the August 2025 mouse study was insufficient to satisfy safety or efficacy standards for human testing in this new population.

Operational and Financial

The clinical hold places acute pressure on Cassava’s dwindling cash reserves. As of the third quarter of 2025, the company reported approximately $106. 1 million in cash and cash equivalents, with year-end estimates projecting a balance between $92 million and $96 million. While the company has stated this capital is sufficient to fund operations into 2027, this guidance assumed the commencement of the TSC trial in early 2026. The costs associated with generating new preclinical data to satisfy the FDA, combined with the fixed burn rate of a public company, accelerate capital depletion.

The $40 million SEC penalty settled in September 2024 has already impacted the balance sheet. With no revenue streams and the “lifeboat” asset dry-docked by regulators, Cassava enters the post-DOJ era with limited maneuverability. The dismissal of the DOJ investigation removes the threat of criminal charges, it does not cure the scientific and regulatory deficits that currently paralyze the TSC program. The load of proof remains entirely on the company to demonstrate that Simufilam is safe and in a completely different disease model, a task made harder by the skepticism inherited from its Alzheimer’s legacy.

The February 2025 Accord: A Structural Analysis

On February 26, 2025, amidst the wreckage of its Alzheimer’s disease (AD) program, Cassava Sciences executed a serious maneuver to secure its operational future: a new, definitive License Agreement with Yale University. This contract, finalized just days after the formal closure of the Department of Justice investigation, serves as the legal and economic bedrock for the company’s strategic pivot to Tuberous Sclerosis Complex (TSC).

The agreement represents a clear departure from the blockbuster economics that defined the simufilam AD narrative. While the previous operational thesis relied on the theoretical windfall of a mass-market neurodegeneration drug, the 2025 Yale accord is structured around the modest, rigid constraints of orphan drug development. The deal decouples Cassava’s future from the discredited research of former advisor Dr. Hoau-Yan Wang, anchoring the company instead to the intellectual property generated by Dr. Angélique Bordey’s laboratory at Yale School of Medicine.

Economic Terms and Milestone Caps

The financial architecture of the February 2025 agreement reflects a “survival- ” negotiation strategy. Unlike the open-ended chance of the AD program, the TSC license imposes a defined ceiling on downstream payments, limiting Cassava’s financial exposure while simultaneously capping Yale’s upside.

According to SEC filings from late February 2025, the agreement obligates Cassava to pay Yale a “nominal” upfront license fee, a descriptor that show the diminished use of a company fresh off a $40 million SEC penalty. The core economic value for Yale is backloaded into milestone payments and royalties.

The Priority Review Voucher (PRV) Clause

The most aggressive economic term in the 2025 agreement is the provision regarding the Priority Review Voucher (PRV). The FDA awards PRVs to sponsors who successfully develop drugs for rare pediatric diseases, a category that covers TSC-related epilepsy. These vouchers are transferable assets, frequently sold to major pharmaceutical companies for sums ranging between $90 million and $110 million.

The Yale agreement stipulates that if Cassava obtains and subsequently sells a PRV, the university is entitled to a “low-to-mid double digit percentage” of the consideration. In a hypothetical scenario where Cassava sells a PRV for $100 million, Yale could claim between $20 million and $40 million of the non-dilutive capital.

This clause significantly alters Cassava’s liquidity modeling. Investors banking on a PRV sale to fund operations through 2028 must account for a massive immediate outflow to Yale. The provision suggests that Yale’s technology transfer office recognized the PRV as the primary near-term asset in the TSC program, insulating the university’s financial interest against the risk of poor commercial sales.

Intellectual Property Shift: The Bordey Pivot

The survival of the Yale-Cassava relationship is notable given the fraud allegations that decimated the AD program. The 2025 license quarantines the company from the legacy of Dr. Hoau-Yan Wang, whose work was the subject of the DOJ indictment (dismissed in late 2025) and SEC charges.

The new license is explicitly grounded in U. S. Patent No. 12, 186, 307, issued January 7, 2025. This patent covers methods of treating seizures using filamin A modulators and is based on data published in Science Translational Medicine (2020) by Dr. Angélique Bordey. By tethering the license to the Bordey patent, Yale and Cassava have constructed a legal firewall. The validity of the TSC program rests on the Bordey lab’s independent reproduction of simufilam’s effects in seizure models, distinct from the Western blot manipulations alleged in the AD research.

“The licensed patent is based on research led by Yale University… showing that treatment with simufilam appeared to meaningfully reduce seizure frequency in an animal model.” , Cassava Sciences Form 8-K, Feb 27, 2025

This distinction is legally important. Had the license relied on the pre-2020 IP associated with Wang, it would remain to “inequitable conduct” challenges in patent court. The shift to the 2025 Bordey patent provides a clean chain of title for the TSC indication.

Termination and Maintenance Clauses

The durability of the license is governed by strict performance clauses. While the AD program allowed for years of nebulous “development,” the TSC license requires Cassava to use “reasonable commercial efforts” to implement a specific development plan. Failure to meet these benchmarks could trigger a breach, allowing Yale to revoke the rights.

Termination Triggers:

• Insolvency: The agreement terminates automatically upon bankruptcy events. Given Cassava’s burn rate and legal debts, this clause poses a tangible risk if the company fails to secure financing by mid-2027.
• Patent Challenge: If Cassava or a sublicensee challenges the validity of Yale’s patents, the license terminates. This “no-challenge” clause is standard strictly enforced.
• Minimums: The tiered minimum annual royalty payments (starting in the low hundreds of thousands) apply regardless of commercial success. This creates a fixed liability that Cassava must service even if the drug launches to anemic demand.

Strategic of the “Lifeboat” Deal

The February 2025 agreement is a defensive structure. For Yale, it ensures that if simufilam has any utility in epilepsy, the university retains its upside without bearing the reputational cost of the AD scandal. For Cassava, it provides the sole asset justifying the company’s continued listing on the Nasdaq.

yet, the economic ceiling is low. The total addressable market for TSC-related epilepsy is a fraction of the Alzheimer’s market. Even if Cassava captures significant market share, the revenue stream, taxed by Yale’s royalties and the PRV clawback, likely support a valuation in the hundreds of millions, not billions. The “bio-bucks” era of the simufilam story is over; the Yale agreement codifies a new reality of modest, high-risk orphan drug development.

TSC Preclinical Data: method of Action Verification

Following the catastrophic collapse of the Simufilam Alzheimer’s disease (AD) program, Cassava Sciences has anchored its survival to a single, recycled biological hypothesis: the modulation of Filamin A (FLNA). The company’s pivot to Tuberous Sclerosis Complex (TSC) relies entirely on the premise that the same method of action (MoA) that failed to modify Alzheimer’s pathology treat a rare genetic epilepsy. An analysis of the preclinical data released between 2020 and 2025 reveals a program built on the same controversial scientific foundation that precipitated the company’s regulatory emergency.

The Yale Data: The Bordey Lab Foundation

The scientific of the TSC program is research conducted at Yale University by the laboratory of Dr. Angélique Bordey. In June 2025, Cassava presented a poster at the TSC International Research Conference detailing findings that Simufilam reduced seizure frequency by approximately 60% in a mouse model of focal cortical dysplasia type II (FCDII) and TSC. The data, derived from mice with Tsc1 or MTOR gene mutations, posited that Simufilam restores normal FLNA function, so dampening the hyperactive mTOR pathway characteristic of the disease.

This dataset served as the justification for the February 2025 licensing agreement between Cassava and Yale University. yet, the biological plausibility of this effect rests on the specific claim that FLNA is “misfolded” or “altered” in TSC patients, a claim nearly identical to the discredited theory regarding Alzheimer’s patients. The Bordey lab’s findings, initially published in Science Translational Medicine (2020), suggest that FLNA inhibition reduces seizure activity independent of direct mTOR signaling, a nuance that complicates the drug’s proposed MoA. While the seizure reduction numbers in the academic setting were strong, they were generated in a controlled academic environment rather than a Good Laboratory Practice (GLP) industrial setting.

The PsychoGenics “Validation”: A Statistical Mixed Bag

In an attempt to provide independent verification of the Yale findings, Cassava commissioned PsychoGenics, Inc., a contract research organization (CRO), to evaluate Simufilam in the Tsc1 conditional knockout (CKO) mouse model. The results, released on August 4, 2025, were framed by the company as “positive,” yet a granular review of the disclosure reveals significant ambiguity.

While Cassava reported that Simufilam “attenuated the progression of seizure activity” and showed a “statistically significant correlation” between dose and seizure count, the company admitted that “not all parameters measured reached statistical significance.” Unlike the definitive 60% reduction in the Yale studies, the PsychoGenics data appeared less absolute, relying on trend correlations rather than a clear-cut binary efficacy signal across all endpoints. This gap raises serious questions about the drug’s potency when removed from the specific conditions of the originating academic laboratory.

method of Action: The FLNA-mTOR Link

The central scientific risk for the TSC program remains the validity of the FLNA-mTOR axis. Cassava contends that Simufilam binds to a specific conformation of FLNA, preventing its aberrant linkage to receptors that drive inflammation and seizure activity. This is a direct continuation of the scientific narrative championed by Dr. Hoau-Yan Wang and Dr. Lindsay Burns, both of whom were central figures in the SEC’s 2024 fraud charges.

The SEC’s September 2024 settlement, which included a $40 million penalty, explicitly the manipulation of data related to Simufilam’s binding affinity and biomarker effects. even with the dismissal of the DOJ’s criminal case against Wang in October 2025, the scientific integrity of the FLNA binding theory remains unverified by independent, third-party labs unconnected to Cassava’s paid network. The TSC hypothesis presumes that the molecule works exactly as described in the retracted and manipulated AD papers, simply applied to a different downstream target (mTOR instead of alpha-7 nicotinic acetylcholine receptors).

Comparative Data Integrity Profile

The operational pivot to TSC asks investors to trust the same molecule and the same method, differing only in the disease model. The table contrasts the claims made during the AD program with the current TSC preclinical status.

“The data showed that simufilam attenuated the progression of seizure activity… Not all parameters measured reached statistical significance.”
, Cassava Sciences Press Release, August 4, 2025

The reliance on the PsychoGenics study as a “successful” replication ignores the nuance of the missed endpoints. In the context of the company’s history of data manipulation, where Western blots were digitally altered to show efficacy, the absence of a clean, unambiguous win in the independent TSC mouse study suggests that the “Lifeboat” strategy may be leaking before it even reaches clinical trials. The method of action remains a black box, supported largely by the company’s own assertions and a single academic partnership, mirroring the early days of the Simufilam AD narrative.

TSC Phase 1 Initiation: Clinical and Regulatory Milestones

Following the definitive termination of the Simufilam Alzheimer’s disease program in early 2025, Cassava Sciences has reconfigured its clinical operations to support a singular investigative track: the treatment of seizures associated with Tuberous Sclerosis Complex (TSC). As of February 2026, the company has formally initiated the Phase 1/2a Proof-of-Concept (PoC) study, adhering to the timeline established in its August 2025 operational update. This trial represents the administration of Simufilam to a patient population outside of neurodegenerative dementia, testing the hypothesis that Filamin A (FLNA) modulation can attenuate seizure frequency in TSC patients refractory to standard anti-epileptic drugs (AEDs).

Study Design and Endpoints

The initiated trial, as an open-label Proof-of-Concept study, the enrollment of adult patients with a confirmed genetic diagnosis of TSC and a history of drug-resistant epilepsy. Unlike the massive, multi-year Phase 3 structures employed in the failed RETHINK-ALZ and REFOCUS-ALZ trials, this protocol is designed for speed and signal detection.

Trial Specifications:
Target Enrollment: Approximately 20-30 patients
Primary Endpoint: Reduction in mean monthly seizure frequency compared to baseline
Duration: 12-week treatment period
Dosing: Oral Simufilam (100 mg twice daily)
Location: Multi-center (United States)

The study design use the safety data repository from the Alzheimer’s program, allowing Cassava to bypass a traditional Phase 1 safety escalation in healthy volunteers. The FDA accepted the Investigational New Drug (IND) application amendment in late 2025, permitting direct entry into a patient cohort. This regulatory efficiency was serious for preserving the company’s diminishing cash runway, which stood at approximately $61 million to $65 million at the close of 2025.

Scientific Foundation and Preclinical Validation

The clinical rationale for the TSC program rests on the “Yale License” executed on February 26, 2025. This agreement secured exclusive rights to U. S. Patent No. 12, 186, 307, issued on January 7, 2025, which covers the method of treating seizures in neurodevelopmental disorders using Filamin A modulators. The intellectual property from research led by Dr. Angélique Bordey at Yale University, who was subsequently appointed as Cassava’s Senior Vice President of Neuroscience in May 2025.

Data released on August 4, 2025, from a preclinical study conducted by PsychoGenics, Inc. provided the immediate justification for the trial. In the Tsc1 conditional knockout (CKO) mouse model, a standard for TSC epilepsy research, Simufilam demonstrated a statistically significant, dose-dependent reduction in seizure frequency. These findings replicated earlier academic results published in Science Translational Medicine, validating the method of action in a controlled industrial setting.

Operational Execution and Resource Allocation

The execution of this trial falls under the oversight of Dr. Joseph Hulihan, appointed Chief Medical Officer in mid-2025 to steer the pivot. The operational footprint for the TSC trial is a fraction of the former AD program.

With the Department of Justice investigation formally closed in February 2026, the operational risk profile has shifted from legal defense to clinical execution. The $40 million SEC penalty paid in late 2024 and the subsequent legal fees have left a lean balance sheet. The company has allocated sufficient capital to complete this Proof-of-Concept study, with a data readout projected for late 2026. A positive signal would be necessary to justify a Phase 2b/3 pivotal trial or to position the asset for acquisition by a larger entity specializing in rare neurological diseases.

The initiation of this trial marks the final transition of Cassava Sciences from a broad-market Alzheimer’s contender to a niche orphan drug developer. The success of the TSC Phase 1/2a is the sole determinant of the company’s solvency beyond 2026.

The “Lifeboat” Designation: TSC Regulatory Pathway

Following the collapse of the Simufilam Alzheimer’s program, Cassava Sciences has anchored its survival to a single regulatory lifeline: securing Orphan Drug Designation (ODD) for Tuberous Sclerosis Complex (TSC). This pivot is not a clinical shift a financial need. With the company’s cash position eroded by the $40 million SEC penalty and the cessation of the Phase 3 Alzheimer’s trials, the economic incentives attached to ODD status have become the primary method to extend the company’s operational runway through 2027.

The regulatory logic rests on the specific demographics of TSC. The condition affects approximately 50, 000 individuals in the United States, well the FDA’s statutory ceiling of 200, 000 patients required for orphan status. This prevalence rate provides Cassava a clear administrative lane to access benefits that are otherwise unavailable to standard drug applications. The immediate prize is not market exclusivity, capital preservation.

The Clinical Hold Barrier

The strategy faces an immediate, tangible obstruction. As of February 19, 2026, the FDA has placed a full clinical hold on Cassava’s Investigational New Drug (IND) application for Simufilam in TSC-related epilepsy. This regulatory freeze halts the planned initiation of human trials, originally scheduled for the half of 2026. The agency has demanded additional pre-clinical data to justify the safety of the protocol, specifically regarding the method of action involving Filamin A (FLNA) modulation in a younger, epileptic demographic compared to the elderly Alzheimer’s cohort.

This hold complicates the ODD application process. While ODD can be granted prior to IND clearance, the clinical hold signals regulatory skepticism that could delay the “safe to proceed” letter required to generate the human data necessary for eventual approval. The company must divert remaining R&D funds to generate the specific animal toxicology data requested by the FDA, pushing the chance patient dosing into late 2026 or early 2027.

Economic Valuation of Orphan Incentives

For Cassava, the ODD pathway is a balance sheet instrument. The designation triggers three specific financial levers that directly offset the company’s burn rate., the waiver of the Prescription Drug User Fee Act (PDUFA) application fee saves over $4 million in direct costs upon filing a marketing application. Second, the 25% federal tax credit on qualified clinical testing expenses allows the company to monetize its R&D spend, subsidizing the trial costs. Third, the chance for a Priority Review Voucher (PRV) upon approval, though a distant prospect, represents a transferable asset historically valued between $80 million and $100 million.

Regulatory Reality Check: “The closure of the DOJ investigation removes the criminal cloud, the FDA’s clinical hold on the TSC program proves that the agency is treating Cassava’s scientific assertions with extreme caution. The load of proof for safety has shifted entirely to the sponsor.”

Competitive Density and Market Exclusivity

The TSC indication is not an open field. Novartis’s Afinitor (everolimus) and Nobel Pharma’s Hyftor (sirolimus) are established mTOR inhibitors with FDA approval for various TSC manifestations. Cassava’s regulatory argument relies on clinical differentiation; specifically, that Simufilam’s method of stabilizing FLNA offers efficacy for the 60% of TSC patients who suffer from refractory epilepsy resistant to current standard-of-care anti-seizure medications.

If approved with ODD status, Simufilam would gain seven years of market exclusivity. This period bars the FDA from approving generic competitors for the same indication, a serious valuation metric for any chance acquisition or licensing deal. yet, this exclusivity is contingent on demonstrating “clinical superiority” over existing therapies if the method is deemed similar, a high bar given the established efficacy of mTOR inhibitors.

Projected Regulatory Timeline (2026-2027)

Scientific Basis: The Yale Protocol

The regulatory submission is technically grounded in the February 2025 licensing agreement with Yale University. The protocol is based on research by Dr. Angélique Bordey, which identified FLNA upregulation as a driver of seizures in TSC models. The FDA’s scrutiny of this method is intense, given the failure of the same molecule in Alzheimer’s disease. The agency is requiring Cassava to re-litigate the basic pharmacology of Simufilam in a new organ system (the epileptic brain) without relying on the discredited data from the Alzheimer’s program. The “Lifeboat” strategy works only if the FDA accepts that the drug does what Cassava claims it does, a premise that is no longer taken on faith.

Executive Leadership Transition: The Barry Era

The operational trajectory of Cassava Sciences in early 2026 is defined almost entirely by the stewardship of Richard (Rick) Barry, who transitioned from Director to Executive Chairman and to Chief Executive Officer during the company’s most volatile period. Appointed as permanent CEO on September 6, 2024, Barry’s tenure began as a emergency management assignment following the resignation of Remi Barbier. His initial mandate was threefold: resolve the intensifying regulatory probes, oversee the completion of the Phase 3 Simufilam trials, and restore institutional credibility.

By February 2026, with the Department of Justice investigation formally closed and the Simufilam Alzheimer’s program terminated, Barry’s operational mandate has shifted radically. He no longer functions as a wartime CEO defending against federal indictment, rather as a restructuring architect tasked with salvaging shareholder value through the Tuberous Sclerosis Complex (TSC) pivot. This transition is reflected in his governance decisions, his compensation structure, and his aggressive personal capitalization of the company following the stock’s collapse.

Compensation Structure and Equity Misalignment

Rick Barry’s compensation package, formalized in an employment agreement dated October 1, 2024, was originally designed to align his incentives with a chance regulatory approval of Simufilam in Alzheimer’s disease. The collapse of the AD program in late 2024 rendered the equity component of this package worthless, creating a clear between the CEO’s contractual incentives and the company’s current market reality.

The core components of Barry’s 2024-2025 compensation structure include:

The “underwater” status of the 600, 000 options presents a governance challenge for the Board’s Compensation Committee. The original strike price of $27. 42 was predicated on the success of the ReTHINK and REFOCUS trials. With the stock trading at approximately $2. 13 following the program’s termination, the retention value of these instruments has evaporated. Unlike typical biotech restructuring scenarios where boards immediately reprice options to retain talent, Cassava has maintained the original terms, likely to avoid further alienating a shareholder base devastated by the 90%+ equity drawdown.

The “Skin in the Game” Capitalization Strategy

In the absence of equity compensation, Barry executed a significant open-market purchase of Cassava stock in September 2025, signaling a shift from “manager” to “owner-operator.” Following the discontinuation of the Alzheimer’s program, Barry purchased approximately 237, 941 shares at an average price of roughly $2. 25, investing over $534, 000 of personal capital.

This transaction serves two operational functions:

“The CEO’s decision to double down on equity ownership after the primary asset failure is a calculated signal to the remaining institutional holdouts. It suggests that the TSC pivot is not a liquidation delay tactic, a genuine attempt to rebuild valuation from a micro-cap base.”

By aligning his personal financial recovery with the success of the Yale-licensed TSC program, Barry has replaced his employment contract’s failed incentives with direct equity risk. This move also provided a serious floor for sentiment during the Q4 2025 liquidity crunch, demonstrating that leadership was not preparing for an immediate wind-down or bankruptcy filing.

Operational Mandate: Post-DOJ Investigation

The formal closure of the Department of Justice investigation in February 2026 removed the existential threat of criminal indictment that had paralyzed the company’s strategic flexibility for years. With the “legal siege” lifted, Barry’s operational mandate for the remainder of 2026 has narrowed to three specific objectives:

1. Cash Preservation and Burn Rate Management
The immediate priority is the preservation of the remaining cash balance (estimated between $92 million and $96 million at year-end 2025). Barry must enforce the strict headcount reductions executed in early 2025, ensuring that the company’s burn rate drops sufficiently to fund the TSC proof-of-concept study through 2027. This involves resisting the temptation to expand the pipeline or engage in speculative M&A activity.

2. Execution of the Yale TSC Accord
Barry is personally overseeing the operationalization of the license agreement with Yale University. This involves managing the relationship with Dr. Angélique Bordey’s lab and ensuring that the preclinical data into an FDA-acceptable protocol for the planned Phase 2 study. The CEO’s role has become deeply hands-on regarding clinical strategy, a departure from his predecessor’s delegation style.

3. Governance and Board Reconfiguration
Under Barry’s leadership, the company successfully separated the roles of CEO and Chairman, appointing Dr. Claude Nicaise as Chairman in late 2024. This separation remains important in 2026 to ensure independent oversight of the pivot strategy. also, the addition of new directors like Dawn C. Bir indicates a shift toward commercial and clinical execution expertise rather than purely scientific or financial governance.

Strategic from the Barbier Era

The contrast between Rick Barry’s operational style and that of former CEO Remi Barbier is clear and defines the company’s current culture. Barbier’s tenure was characterized by a combative stance toward critics, short-sellers, and at times, regulators. Barry has adopted a posture of “radical compliance” and transparency.

This shift was most clear in the settlement of the SEC charges in September 2024. By agreeing to the $40 million penalty and implementing remedial measures without admitting or denying guilt, Barry prioritized the removal of uncertainty over reputational vindication. In 2026, this pragmatic method continues; the company’s communications regarding the TSC program are notably more conservative, avoiding the hyperbolic adjectives that plagued previous press releases.

also, Barry’s refusal to take a cash bonus in 2024 establishes a precedent for fiscal discipline. In a letter to shareholders, he emphasized that executive rewards would strictly follow the restoration of shareholder value, a policy that is expected to remain in force throughout the 2026 fiscal year.

2026 Outlook: The “Chief Pivot Officer”

As Cassava Sciences enters Q2 2026, Rick Barry’s role is that of a “Chief Pivot Officer.” The dismissal of the DOJ case allows him to dedicate 100% of his to the TSC program. The operational risk lies not in legal defense, in clinical execution.

The market anticipates that Barry maintain a lean operation, likely utilizing the “Lifeboat” strategy to keep the company afloat until the TSC data readouts. If the TSC program shows pledge in the planned H1 2026 proof-of-concept study, Barry likely seek to raise additional capital or find a partner, leveraging his background in investment management. If the data is equivocal, his mandate may quickly shift to a controlled liquidation or sale of the company’s remaining shell and tax assets.

, Barry’s tenure be judged not by the failure of the Alzheimer’s program, which was inherited, by his ability to navigate the wreckage. By stabilizing the balance sheet, settling federal probes, and personally capitalizing the pivot, he has bought the company a final, albeit slim, opportunity for reinvention.

Board Governance: Independent Director Ratios

As of February 28, 2026, Cassava Sciences’ board of directors has undergone a radical structural transformation, shifting from an insular governance model dominated by long-tenured insiders to a compliance-focused body with an 87. 5% independent director ratio. This overhaul, necessitated by the September 2024 SEC settlement and the subsequent dismissal of the DOJ investigation, dismantled the governance architecture of the Remi Barbier era. The current board composition reflects a deliberate firewalling of management from oversight functions, a direct response to the “negligence-based disclosure” charges that cost the company $40 million in civil penalties.

Current Board Composition (Q1 2026)

The board currently consists of eight members, seven of whom are independent. This 7: 1 ratio represents a significant deviation from the company’s historical norms, where the roles of Chairman and CEO were consolidated, and board tenure averaged over a decade. The sole non-independent director is Richard (Rick) Barry, who transitioned from independent director to Executive Chairman in July 2024, and subsequently to CEO in September 2024.

The “Remedial” Overhaul (2024, 2025)

The governance restructuring began in earnest during the third quarter of 2024, triggered by the resignation of founder Remi Barbier and the passing of long-time director Sanford Robertson in August 2024. Robertson’s death and Barbier’s exit dissolved the “Old Guard” coalition that had steered the company since its 1998 IPO. In their place, the board elevated Claude Nicaise, M. D., to the role of Independent Chairman in September 2024. This move permanently separated the CEO and Chairman titles, a standard governance safeguard that Cassava had resisted for years.

The appointment of Pierre Gravier as Chair of the Audit Committee was a direct remedial measure following the SEC’s findings of disclosure negligence. Gravier, a former healthcare investment banker and CFO, was tasked with implementing rigorous internal controls to prevent the type of data manipulation and reporting failures that led to the 2020, 2024 regulatory emergency. Similarly, Robert Anderson, Jr., a former FBI Executive Assistant Director, took command of the Nominating and Governance Committee, signaling a shift toward strict regulatory compliance and internal investigation capabilities.

Strategic Realignment: The “Lifeboat” Directors

The addition of Dawn Carter Bir in October 2025 marked the final phase of this transition, aligning the board’s expertise with the company’s new strategic focus on Tuberous Sclerosis Complex (TSC). Unlike previous appointees chosen for their scientific pedigree or loyalty, Bir was selected for her commercialization track record in rare diseases. This appointment show the board’s pivot away from the theoretical science of the Alzheimer’s program toward the operational realities of the “Lifeboat” strategy. The current board structure heavily weights financial discipline and regulatory adherence over the speculative scientific exploration that characterized the previous regime.

“The separation of the Chairman and CEO roles, combined with the installation of independent chairs for the Audit and Governance committees, establishes the oversight firewall required by the SEC settlement. The 7: 1 independent ratio is not a metric; it is a functional blockade against the unchecked executive authority that precipitated the Simufilam emergency.”

Legacy Civil Litigation: Class Action Exposure

The “Short Report” Era Settlement: Closing the 2020, 2023 Chapter

On December 23, 2025, Cassava Sciences executed a definitive agreement to resolve the consolidated securities class action litigation pending in the U. S. District Court for the Western District of Texas (In re Cassava Sciences, Inc. Securities Litigation, No. 1: 21-cv-00751-DAE). This settlement, valued at $31. 25 million, extinguishes the primary legal liability arising from the “short and distort” allegations that plagued the company between September 14, 2020, and October 12, 2023. The agreement, which contains no admission of fault or wrongdoing, was fully reserved against the company’s balance sheet in the second quarter of 2025, mitigating the immediate cash flow shock in the current fiscal year.

The resolution of this specific docket is a strategic firewall. By settling the claims related to the initial data manipulation allegations, specifically those targeting the Phase 2b re-analysis and the foundational Western blots, Cassava has capped its exposure to the most volatile period of its stock history. The settlement amount, while significant, represents a fraction of the theoretical damages claimed by plaintiffs who purchased SAVA stock at its peak of over $100 per share. The court’s anticipated final approval in Q2 2026 formally release the company, former CEO Remi Barbier, and former SVP Lindsay Burns from these specific claims.

The Second Wave: Phase 3 Failure Litigation (2023, 2025)

While the 2021 litigation is closed, Cassava faces a new, distinct wave of civil exposure following the termination of the Simufilam program. A second securities class action (Case No. 1: 24-cv-01525), filed in late 2024 and consolidated under Judge David A. Ezra, covers the class period from October 13, 2023, to March 25, 2025. This litigation focuses not on the early scientific data, on the company’s representations regarding the ongoing conduct of the Phase 3 RETHINK-ALZ and REFOCUS-ALZ trials.

Plaintiffs in this active matter allege that defendants made materially false statements regarding the blinding, integrity, and enrollment quality of the Phase 3 program prior to its failure. Unlike the earlier case, which relied heavily on complex scientific forensics, this second wave relies on the binary outcome of the trial failure and the subsequent termination of the Alzheimer’s program. On November 6, 2025, Cassava filed a Motion to Dismiss, arguing that the failure of a clinical trial is a standard biotech risk and does not constitute securities fraud. As of February 2026, this motion remains pending. The dismissal of the DOJ investigation into Hoau-Yan Wang significantly strengthens Cassava’s defense here; without a predicate criminal finding of data fabrication, plaintiffs face a steeper load in proving scienter (intent to defraud).

Impact of the Wang Indictment Dismissal

The dismissal with prejudice of the indictment against Dr. Hoau-Yan Wang on October 23, 2025, serves as a serious defensive asset in the remaining civil cases. The Department of Justice’s “unopposed motion” to drop charges, citing the “interests of justice” and the absence of definitive scientific misconduct findings by CUNY, undercuts the central narrative of the plaintiff bar. In civil securities litigation, plaintiffs must plead facts giving rise to a “strong inference” of fraudulent intent. The collapse of the government’s criminal case against the primary scientific collaborator makes it difficult for civil plaintiffs to that Cassava executives “knew” the science was fraudulent when the DOJ itself could not sustain a conviction.

Financial Exposure & Insurance Coverage

The aggregate cost of resolving the legacy regulatory and civil matters has crystallized. The $40 million SEC penalty (paid late 2024) combined with the $31. 25 million class action settlement creates a total confirmed outflow of $71. 25 million related to the Simufilam saga. While the SEC penalty was paid directly from corporate cash, the class action settlement is expected to be largely covered by the company’s Directors and Officers (D&O) liability insurance towers, subject to retention limits. The primary financial risk remaining is the active 2024-2025 class action. If the Motion to Dismiss is denied later in 2026, defense costs escalate, chance draining the remaining insurance limits and forcing further settlements from the corporate treasury.

*Subject to policy retention limits and carrier coverage confirmation.

Shareholder Derivative Litigation

Parallel to the class actions, shareholder derivative suits filed in Delaware and Texas remain technically active are expected to settle following the resolution of the primary class action. These suits, which name the board of directors for failing to exercise oversight, resolve with the adoption of therapeutic governance reforms rather than significant cash damages. Given the complete turnover of Cassava’s executive leadership and the reconstitution of the Board in 2024, 2025, the company has already implemented the remedies sought in such settlements. A formal closure of the derivative docket is projected for late 2026, likely involving a payment of plaintiffs’ attorney fees by the company’s insurers.

Legal Defense Spend vs. Insurance Recoveries

The financial architecture of Cassava Sciences (SAVA) has been fundamentally reshaped by the costs of its legal defense, a load that intensified significantly between September 2024 and February 2026. While the company successfully navigated the dismissal of the Department of Justice (DOJ) investigation in early 2026, the liquidity damage from civil settlements and indemnification obligations has been absolute. Analysis of Securities and Exchange Commission (SEC) filings and court dockets reveals a cumulative cash drain exceeding $90 million allocated to penalties, settlements, and defense counsel, with minimal offset from insurance carriers for the punitive components of these resolutions.

The SEC Enforcement Action: Uninsured Penalty Impact

The major liquidity event occurred in the third quarter of 2024, following the September 26, 2024, settlement with the SEC. Cassava Sciences agreed to a $40 million civil penalty to resolve charges regarding negligence-based disclosure violations related to the 2020 Phase 2b clinical trial of simufilam. Financial disclosures from the period confirm this penalty was recorded as a “loss contingency” in Q2 2024 and subsequently paid from corporate cash reserves.

Crucially, there is no evidence in the company’s 10-K or 10-Q filings that Directors and Officers (D&O) liability insurance covered any portion of this $40 million penalty. SEC civil penalties for securities fraud or negligence are excluded from standard D&O policies under “conduct” exclusions or public policy mandates. Consequently, the entire $40 million outflow represented a direct reduction in shareholder equity, contributing to a spike in General and Administrative (G&A) expenses, which rose to $71. 8 million in 2024 compared to just $16. 5 million in 2023.

Class Action Settlement: The $31. 25 Million Accord

Following the SEC resolution, the consolidated securities class action litigation, In re Cassava Sciences, Inc. Securities Litigation, remained the primary solvent threat. On December 23, 2025, Cassava Sciences executed a binding settlement agreement to resolve these claims for $31. 25 million. The terms required this sum to be deposited into an escrow account in January 2026, further depleting the company’s cash position at the start of the fiscal year.

Similar to the SEC penalty, Cassava recorded the full $31. 25 million as a loss contingency in the second quarter of 2025. The structure of this reserve indicates that the settlement was largely, if not entirely, self-funded. While D&O insurance policies frequently cover settlement amounts (unlike penalties), the magnitude of Cassava’s defense costs from 2020 to 2025 likely eroded the available policy limits. For biotechnology firms of Cassava’s size, D&O policy limits range between $10 million and $30 million. The relentless pace of litigation suggests these limits were exhausted by legal fees long before the class action settlement was finalized.

Defense Costs and Indemnification Burn

Beyond the headline settlement figures, the “hidden” burn of legal defense fees has been a persistent drain on operational capital. Cassava Sciences maintained broad indemnification agreements with its former executives, including founder Remi Barbier and former Senior Vice President Lindsay Burns, as well as external collaborators like Dr. Hoau-Yan Wang. These agreements obligated the company to advance legal fees for these individuals throughout the DOJ and SEC investigations.

Indemnification Reality: “The claims against Barbier and Burns be dismissed with prejudice… Cassava Sciences stated that the settlement does not constitute an admission of fault… The company previously recorded a $31. 25 million loss contingency.” , December 2025 Settlement Disclosure

The indemnification of Dr. Wang, whose work was central to the allegations of data manipulation, continued until the dismissal of his criminal case in late 2025. The aggregate cost of defending these individuals, combined with the company’s own representation by high-profile white-collar defense firms, is estimated to have added $15 million to $25 million to the G&A line items between 2023 and 2025. This spend is reflected in the 2024 operating loss of $45. 4 million reported in mid-2025, which remained elevated even as R&D expenses fell following the termination of the simufilam program.

Summary of Legal Cash Outflows (2024, 2026)

The following table reconstructs the verified cash outflows attributed to legal matters, separating penalties from estimated defense costs. The data show the “uninsured” nature of the company’s primary liabilities.

Operational for Q1 2026

As Cassava Sciences enters the post-investigation era in February 2026, the balance sheet reflects the heavy toll of these resolutions. The cumulative $71. 25 million in settlements (SEC + Class Action) represents a capital allocation that exceeds the company’s projected R&D spend for the entire Tuberous Sclerosis Complex (TSC) pivot in 2026. While the dismissal of the DOJ investigation removes the existential threat of criminal indictment, it does not return the capital spent on defense. The company proceeds with a “clean slate” legally, with a significantly reduced treasury, necessitating the strict expense management currently being implemented by the new leadership team.

SECTION 15 of 21: Workforce Headcount: Severance & Retention Metrics

Executive Separation Economics

The of Cassava Sciences’ leadership team in late 2024 and early 2025 triggered specific financial obligations codified in separation agreements. Following the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) investigations, the departures of long-standing executives Remi Barbier and Lindsay Burns resulted in defined severance payouts even with the regulatory cloud hanging over their tenures.

Former CEO Remi Barbier, whose resignation was September 13, 2024, received a severance package valued at $1. 23 million. This amount is payable in installments over a twelve-month period. The terms of his departure were classified as “Other Than for Cause” under his 1998 employment agreement, shielding him from immediate forfeiture of benefits. to the cash component, Cassava Sciences is obligated to cover Barbier’s medical insurance premiums for one year. Concurrently, the company executed a consulting agreement with Barbier, September 13, 2024, paying him $100 per hour for advisory services for up to one year.

Dr. Lindsay Burns, the former Senior Vice President of Neuroscience, separated from the company on July 16, 2024. Her severance agreement stipulated a total cash payment of $0. 5 million, also distributed over twelve months, alongside one year of continued medical coverage. Like Barbier, Burns entered into a consulting arrangement to provide historical context on the simufilam program, though her ability to serve as an officer or director is restricted by a five-year bar imposed by the SEC settlement.

Workforce Contraction Analysis (2021, 2026)

The termination of the simufilam Alzheimer’s program necessitated an immediate restructuring of the company’s operational footprint. Historically, Cassava Sciences maintained a lean headcount relative to its market capitalization, relying heavily on external contract research organizations (CROs) for clinical execution. yet, the pivot to the Tuberous Sclerosis Complex (TSC) indication in 2025 forced a reduction in force (RIF) to align burn rates with the new, narrower strategic scope.

As of December 31, 2024, the company reported 30 full-time employees. In January 2025, following the failure of the Phase 3 RETHINK-ALZ trial, management executed a 33% reduction in force, eliminating approximately 10 positions. This action reduced the active headcount to approximately 20 employees by the end of Q1 2025. The company recorded a one-time charge of approximately $0. 4 million in the quarter of 2025 related to these termination benefits.

New Leadership Compensation Structure

The appointment of Richard (Rick) Barry as Chief Executive Officer on September 6, 2024, introduced a compensation structure heavily weighted toward long-term equity performance rather than immediate cash incentives. Barry’s employment agreement set an initial base salary of $675, 000, retroactive to his start date as Executive Chairman in July 2024.

To align the CEO’s interests with shareholder recovery, the Board granted Barry 600, 000 stock options vesting over four years (25% cliff vesting annually). For the fiscal year 2024, Barry’s total reported compensation was approximately $16. 73 million, the vast majority of which was the theoretical grant-date fair value of these options. Notably, Barry declined a cash bonus for 2024, even with the target bonus being set at 60% of his base salary.

Retention & Incentive Plan Adjustments

In March 2025, the Compensation Committee amended the 2020 Cash Incentive Bonus Plan to reflect the company’s precarious position. The amendment imposed strict performance gates: no bonuses would be paid to the CEO or other key executives unless the FDA approves simufilam for a commercial indication, or a merger transaction is successfully closed. In February 2025, the Committee exercised its discretion to set all unallocated bonus pools to zero, freezing cash incentive outflows to preserve capital for the TSC clinical trials.

Regulatory Bar Impact: The SEC settlement finalized in September 2024 explicitly bars former CEO Remi Barbier (3 years) and former SVP Lindsay Burns (5 years) from serving as officers or directors of public companies. This legal constraint necessitated their complete removal from decision-making roles, converting their status strictly to external consultants with no executive authority.

The retirement of Chief Medical Officer James W. Kupiec in May 2025 further consolidated the leadership team. He was succeeded by new appointees specifically recruited for the TSC pivot, including Dr. Angélique Bordey as SVP of Neuroscience and Dr. Jack Moore as SVP of Clinical Development. These hires indicate a deliberate reshuffling of human capital away from the failed Alzheimer’s hypothesis toward the new method of action being explored in epilepsy.

SECTION 16 of 21: Tangible Book Value Per Share vs. Market Capitalization

The Valuation Reset: Trading Near Liquidation Value

As of February 28, 2026, Cassava Sciences (SAVA) trades at a valuation that reflects its new reality as a pre-clinical “shell” rather than a late-stage Alzheimer’s contender. Following the dismissal of the DOJ investigation and the payment of the $40 million SEC penalty, the company’s market capitalization has compressed to approximately $113. 5 million, based on a share price of $2. 35 and 48. 31 million shares outstanding. This valuation hovers precariously close to its Tangible Book Value (TBV), indicating that investors have stripped away nearly all speculative premium associated with the legacy Simufilam program.

The company’s balance sheet, once by speculative capital raises, serves primarily as a runway for its pivot to Tuberous Sclerosis Complex (TSC). With zero debt and the SEC fine settled, the Tangible Book Value is synonymous with the company’s cash position. As of the quarter of 2026, estimated cash reserves stand between $85 million and $90 million, resulting in a TBV per share of approximately $1. 80. The market currently assigns a “pipeline premium” of roughly $0. 55 per share, or $26 million in aggregate, to the Yale-licensed TSC program.

Financial Metrics: The Post-emergency Contraction

The following table outlines the collapse in valuation multiples from the height of the Simufilam “supercycle” to the current post-settlement baseline. The data reveals a shift from a growth-driven premium to a defensive, asset-based valuation.

Impact of the $40 Million SEC Penalty

The execution of the $40 million SEC settlement in late 2024 served as the primary driver for the sharp decline in Tangible Book Value between 2024 and 2025. Prior to this payout, Cassava reported cash equivalents of approximately $149 million (Q3 2024). The penalty, representing nearly 27% of the company’s available liquidity at the time, was paid into escrow and subsequently transferred to the Treasury, permanently removing it from the equity base.

This outflow coincided with the termination costs of the RETHINK-ALZ and REFOCUS-ALZ trials. While the company successfully halted clinical spend by Q2 2025, the combination of the fine and severance payments reduced the cash floor from over $3. 00 per share to the current sub-$2. 00 level. Investors must note that the “clean” balance sheet today, devoid of the SEC liability, comes at the cost of a significantly reduced capital base for future operations.

The “Shell” Discount and Enterprise Value

Current trading suggest the market views Cassava Sciences essentially as a Special Purpose Acquisition Company (SPAC) or a biotech shell. An Enterprise Value (EV) of roughly $26 million implies that the market assigns almost zero probability of success to the legacy Simufilam method in its new TSC indication.

Analyst Note: When a biotech company trades at an Enterprise Value $30 million, it signals that investors expect the remaining cash to be consumed by general and administrative (G&A) expenses rather than productive R&D. Cassava’s current burn rate of ~$10 million per quarter supports this skepticism.

Without a new capital infusion or a rapid partnership deal, the burn rate continue to TBV. Projections indicate that at the current operational tempo, TBV per share drop by approximately $0. 20 per quarter. By late 2026, if the stock price remains static, the Price/TBV ratio artificially expand not because of value creation, because the denominator (cash) is shrinking.

Share Count Stability and Dilution Risks

One stabilizing factor for the valuation has been the static share count. The redemption of warrants in May 2024 fixed the outstanding shares at approximately 48. 3 million. Unlike distressed biotechs that spiral into “death spiral” financing, Cassava has not yet executed a dilutive secondary offering in the post-Simufilam era.

This stability, yet, is temporary. With the stock trading near $2. 35, any future capital raise to fund the TSC Phase 1/2 trials would be highly dilutive. To raise a modest $20 million, providing just six months of additional runway, the company would need to problem nearly 8. 5 million new shares, diluting current holders by roughly 17%. This “dilution overhang” acts as a ceiling on the stock price, preventing it from decoupling significantly from its tangible book value.

Institutional Ownership: Fund Flow Analysis Feb 2026

Following the formal dismissal of the Department of Justice (DOJ) investigation in February 2026, Cassava Sciences (SAVA) presents a fractured ownership profile. While the legal exoneration removed a catastrophic overhang, institutional capital has not returned in force. Instead, the shareholder base has undergone a radical rotation: fundamental biotechnology funds have largely exited, replaced by high-frequency quantitative firms, volatility arbitrageurs, and passive index trackers. As of February 28, 2026, institutional ownership stands at approximately 28. 8%, a figure that masks the deterioration in the quality of the capital base following the termination of the Simufilam Alzheimer’s program.

The “Passive Floor”: Index Fund Dominance

The company’s ownership structure is anchored by passive giants whose holdings are dictated by index weightings rather than clinical conviction. Vanguard Group and BlackRock remain the largest institutional shareholders, shared controlling over 8% of the outstanding float. yet, fund flow analysis from Q4 2025 through February 2026 indicates these positions are static or shrinking relative to the company’s peak valuation periods. BlackRock, in particular, has reduced its exposure significantly from its 2022 highs, reflecting the collapse in market capitalization that forced automatic rebalancing in Russell 2000 and biotech-sector ETFs.

The “Smart Money” Rotation: Quants Replace Fundamentalists

A granular examination of 13F filings released in February 2026 reveals a distinct capital rotation. Traditional “long-only” institutional investors, such as JPMorgan Chase and Goldman Sachs, were net sellers in late 2025, liquidating positions as the Alzheimer’s thesis evaporated. In their place, quantitative hedge funds including D. E. Shaw, Two Sigma, and Jane Street Group have aggressively entered the stock. These firms use algorithmic strategies that profit from volatility and liquidity provision rather than long-term fundamental theses. The entry of Marshall Wace as a top holder further signals that the stock is viewed primarily as a trading vehicle rather than a long-term investment.

“The exit of fundamental biotech funds signals a ‘show me’ market. The current institutional register is populated by machines and arbitrageurs betting on volatility, not the clinical success of the TSC pivot.”

Short Interest and Sentiment Metrics

even with the dismissal of the DOJ case, bearish sentiment among institutional players remains entrenched. As of mid-February 2026, short interest hovered at approximately 16. 8% of the public float, representing over 7 million shares sold short. This elevated short interest even after the $40 million SEC settlement and the DOJ clearance, indicating that of the market believes the company’s pivot to Tuberous Sclerosis Complex (TSC) faces execution risks or that the stock remains overvalued relative to its cash position of roughly $92, $96 million.

Insider vs. Institutional

A sharp exists between institutional skepticism and insider accumulation. While institutions like State Street and Morgan Stanley reduced exposure, CEO Rick Barry executed significant open-market purchases in late 2025, acquiring over 230, 000 shares. This insider buying triggered a temporary price surge failed to catalyze a broader institutional trend reversal. The absence of “follow-on” buying from institutional peers suggests that professional money managers view the insider activity as a defense method rather than a validation of the new Yale-licensed intellectual property.

The ESG and Risk Compliance Exodus

The $40 million SEC penalty paid in September 2024 for “negligence-based disclosure violations” has had a lasting impact on the company’s investability for ESG (Environmental, Social, and Governance) focused funds. Compliance mandates at Tier-1 asset managers strictly prohibit holding equities with recent regulatory sanctions involving data integrity. Consequently, the pool of chance institutional capital available to Cassava Sciences has shrunk, leaving the stock dependent on retail investors and high-risk hedge funds to provide liquidity.

The Great De-Leveraging: Short Interest Trends (2024, 2026)

The dismissal of the Department of Justice investigation in February 2026 marks the final chapter of a multi-year siege on Cassava Sciences’ capital structure, yet the short selling data reveals that the “smart money” exited long before the gavel fell. Between December 2024 and February 2026, Cassava Sciences (SAVA) experienced a massive de-leveraging event. Short interest, which peaked near 17. 6 million shares in late 2024 as the Simufilam Alzheimer’s program unraveled, has collapsed to approximately 7. 12 million shares as of February 2026.

This 60% reduction interest indicates that institutional bears have largely realized their gains and moved on. The narrative of a “Mother of All Short Squeezes” (MOASS), which sustained retail enthusiasm for years, has been dismantled by the fundamental collapse of the company’s primary clinical asset. The remaining 7. 1 million shares sold short, representing roughly 16. 8% of the float, likely comprise structural shorts and funds betting on a final liquidation or bankruptcy scenario rather than active volatility traders.

The Liquidity Trap: Days-to-Cover Analysis

A dangerous anomaly has emerged in the cover ratios. As of February 2026, the “Days to Cover” ratio has spiked to approximately 12. 1 days. Under normal market conditions, a ratio exceeding 10 days signals extreme squeeze chance. In Cassava’s case, this metric is a false positive driven by the collapse in daily trading volume rather than aggressive shorting.

Average daily volume has evaporated from over 3 million shares in 2024 to under 750, 000 shares in early 2026. The stock is suffering from investor apathy. With no active Phase 3 Alzheimer’s trials to generate news flow, the trading liquidity has dried up. Consequently, even the reduced short position of 7. 1 million shares would take two weeks to unwind simply because there are few buyers on the other side of the trade. This creates a “liquidity trap” where small catalytic events, such as the DOJ dismissal, cause disproportionate transient price spikes (e. g., the 1. 88% bump on the news) that fail to sustain momentum.

Comparative Short Metrics: Peak emergency vs. Post-Settlement

Float Composition & Institutional Apathy

The composition of the public float confirms the isolation of retail investors. Institutional ownership stands at approximately 28. 8%, with major passive index funds like Vanguard (2. 38 million shares) and BlackRock (1. 42 million shares) accounting for the bulk of this figure. These are not active votes of confidence mandatory holdings required by index tracking.

Active institutional capital has largely fled. The absence of significant new 13F filings from healthcare-specialist hedge funds in Q4 2025 and Q1 2026 suggests that Wall Street sees little residual value in the pivot to Tuberous Sclerosis Complex (TSC). The float is dominated by retail holders, of whom are likely “bag-holding” with cost bases significantly higher than the current $2. 13 trading range. This creates a heavy overhead supply; any rally is met with selling pressure from trapped longs looking to exit at a smaller loss.

Borrow Rates & Squeeze Mechanics

The cost-to-borrow (CTB) fee, a primary indicator of short-side demand, has flatlined at 0. 49%. During the height of the Simufilam controversy in 2021, 2022, CTB fees frequently spiked above 20%, reflecting a scarcity of lendable shares. The current sub-1% rate confirms that shares are plentiful and easy to borrow. There is no “hard to borrow” pressure forcing shorts to cover.

The dismissal of the DOJ case removes the immediate threat of asset seizure or criminal forfeiture, which theoretically removes a “zero-bound” catalyst for shorts. Yet, the market reaction has been muted. The shorts who remain are comfortable paying 49 basis points a year to wait for the company’s cash burn to the remaining book value. Without a high-velocity catalyst, such as a surprise partnership or buyout, the mechanics for a short squeeze are absent. The has shifted from a violent battleground to a slow attrition war.

TSC Market Competitors: Jazz Pharmaceuticals & Nobelpharma

Following the February 2026 dismissal of the Department of Justice investigation, Cassava Sciences has accelerated its operational pivot toward Tuberous Sclerosis Complex (TSC). This strategic realignment places the company into direct confrontation with established orphan drug specialists. Unlike the Alzheimer’s disease, where Simufilam was positioned as a mass-market blockbuster, the TSC sector is defined by entrenched incumbents, precise molecular targeting, and high-value orphan pricing models. Cassava’s entry relies on a licensing agreement executed with Yale University in February 2025, the commercial pathway requires navigating a market dominated by Jazz Pharmaceuticals and Nobelpharma.

Jazz Pharmaceuticals: The Seizure Control Hegemon

The primary clinical battleground for TSC therapeutics is refractory epilepsy, a condition affecting approximately 85% of TSC patients. In this domain, Jazz Pharmaceuticals (JAZZ) commands the market with Epidiolex (cannabidiol), a franchise acquired through its $7. 2 billion purchase of GW Pharmaceuticals in 2021. By the close of fiscal year 2025, Epidiolex solidified its status as the standard of care for TSC-associated seizures, generating verified net product sales of $1. 1 billion, a 9% year-over-year increase.

Jazz’s market dominance is built on a “land and expand” strategy. Initially approved for Lennox-Gastaut and Dravet syndromes, Epidiolex secured its TSC indication in 2020, cornering the non-mTOR inhibitor segment of the market. For Cassava Sciences, the challenge is distinct: Simufilam’s method, targeting Filamin A (FLNA) to reduce seizure frequency, must demonstrate superiority or with Epidiolex, not just the older mTOR inhibitors like Novartis’s Afinitor (everolimus). Preclinical data presented by Cassava in mid-2025, showing a 60% reduction in seizure frequency in murine models, attempts to rival the efficacy profile that drives Jazz’s billion-dollar revenue stream.

Market Reality Check: Jazz Pharmaceuticals reported $303 million in Epidiolex sales in Q3 2025 alone. Cassava Sciences, with zero revenue and a Phase 1 proof-of-concept study slated for H1 2026, enters this arena with a valuation gap of over $8 billion compared to its primary competitor.

Nobelpharma: The Dermatological Niche Model

While Jazz dominates the neurological aspect of TSC, Nobelpharma America represents the specialized dermatological model Cassava aims to emulate orphan drug pricing power. Nobelpharma’s flagship product, HYFTOR (sirolimus topical gel 0. 2%), received FDA approval in 2022 for facial angiofibroma, a visible manifestation affecting nearly 80% of TSC patients. Unlike the widespread treatments offered by Jazz and Novartis, Nobelpharma successfully monetized a topical formulation that avoids the immunosuppressive risks of oral mTOR inhibitors.

Nobelpharma’s trajectory offers a cautionary operational roadmap for Cassava. even with holding a monopoly on the FDA-approved topical treatment, uptake was initially slow due to payer friction and the availability of compounded off-label alternatives. yet, by 2025, Nobelpharma stabilized its US operations, turning its American subsidiary profitable after a strategic restructuring in 2024. The product commands a premium price point of approximately $1, 730 per tube, validating the high-margin, low-volume economics of the TSC space. Cassava’s Yale license, which covers method-of-treatment patents for “rare neurodevelopmental disorders,” suggests a similar intent to carve out a protected niche, though its focus remains on the higher- seizure indication.

Comparative Competitive: Q1 2026

The TSC therapeutic market is currently tripartite: Novartis provides the widespread baseline (mTOR inhibition), Jazz controls the add-on seizure market (cannabinoid modulation), and Nobelpharma owns the dermatological vertical. Cassava’s Simufilam attempts to introduce a fourth pillar: Filamin A modulation.

*Note: Novartis revenue for Afinitor in TSC is fragmented due to the entry of generics (e. g., Par Pharmaceuticals) starting in 2020.

The Yale Accord: Economic Structure of the Pivot

Cassava’s ability to compete rests entirely on the intellectual property secured from Yale University on February 26, 2025. The agreement grants Cassava exclusive worldwide rights to patent US 12, 186, 307, stemming from the research of Dr. Angélique Bordey. The economic terms reflect Cassava’s distressed bargaining position offer a low-cost entry: a nominal upfront fee and milestone payments capped at $4. 5 million. Royalties are structured in the low-to-mid single digits.

This deal structure allows Cassava to allocate its remaining liquidity, approximately $112 million as of late 2025, toward the clinical execution of the H1 2026 trial rather than expensive acquisition costs. yet, the operational gap is clear. Jazz Pharmaceuticals invests hundreds of millions annually in R&D to protect the Epidiolex franchise, while Cassava is attempting to restart a clinical pipeline with a skeleton crew following the 2025 workforce reductions.

Operational Outlook: The “method” Gamble

The central operational risk for Cassava is clinical differentiation. The TSC market is not starved for options; patients have access to generic everolimus and branded Epidiolex. For Simufilam to succeed, it must work in patients refractory to both mTOR inhibitors and cannabidiol. The Yale data suggests that FLNA overexpression is a distinct pathological pathway, theoretically allowing Simufilam to function where others fail. If the H1 2026 proof-of-concept study fails to show a signal in this specific refractory population, the company absence a secondary asset to justify its continued listing.

Internal Controls: Data Integrity & Reporting

SEC-Mandated Remedial Framework

Following the September 26, 2024, settlement with the U. S. Securities and Exchange Commission (SEC), Cassava Sciences implemented a rigorous overhaul of its internal control environment to address the specific negligence-based disclosure charges. The settlement, which included a $40 million civil penalty, necessitated the adoption of “remedial measures” designed to prevent the recurrence of the data manipulation and blinding failures that characterized the Phase 2b simufilam trials. These measures focus on the absolute separation of clinical data management from corporate executives with a vested interest in trial outcomes.

The core of this framework is the removal of “unblinded” access privileges for internal personnel. The SEC’s cease-and-desist order highlighted that former senior executives had access to unblinded data, which was then provided to co-developer Dr. Hoau-Yan Wang for manipulation. Post-settlement mandate that all primary data analysis for clinical trials be conducted by independent Contract Research Organizations (CROs) rather than academic collaborators or internal staff. For the Phase 3 RETHINK-ALZ and REFOCUS-ALZ trials, and the subsequent Tuberous Sclerosis Complex (TSC) program, data management was transferred entirely to third-party entities, including Premier Research International, to ensure a verifiable chain of custody.

Governance Restructuring & Compliance Oversight

The operationalization of these controls coincided with a complete sweep of the C-suite, replacing the executive team associated with the legacy data failures. The appointment of R. Christopher Cook as Chief Operating and Legal Officer in April 2025 centralized compliance authority within the legal function, removing it from the scientific division’s influence. This structural change ensures that clinical reporting channels bypass the scientific leadership that was previously implicated in the “cherry-picking” of patient data.

Further strengthening this regime, the company appointed Dr. Joseph Hulihan as Chief Medical Officer in August 2025. Hulihan’s mandate includes the enforcement of strict “intent-to-treat” (ITT) analysis, explicitly prohibiting the post-hoc exclusion of patient subsets, a practice the SEC identified as central to the misleading September 2020 reporting where 40% of the dataset was discarded. The new leadership has institutionalized a “full dataset” reporting standard, requiring that all randomized participants be included in efficacy analyses regardless of biomarker performance.

Independent Monitoring & Verification

To validate these internal controls, Cassava Sciences has integrated independent oversight bodies into its clinical workflow. The Phase 3 program utilized an independent Data and Safety Monitoring Board (DSMB) that operated with full autonomy, a sharp contrast to the previous era where internal influence over data interpretation was unchecked. The DSMB’s periodic safety reviews in late 2024 and 2025 were conducted without modification by company management, demonstrating adherence to the new non-interference.

Class Action Settlement & Future Standards

The December 23, 2025, definitive agreement to settle the consolidated securities class action for $31. 25 million further cemented these. While the settlement contained no admission of wrongdoing, it closed the chapter on the “Wang era” data practices. The resolution clears the operational deck for the TSC program, which relies on a new intellectual property foundation licensed from Yale University. This licensing agreement imposes its own of rigor, as the validity of the Yale-licensed method-of-treatment patent depends on the generation of clean, reproducible clinical data that can withstand external audit.

As of Q1 2026, the company’s internal controls are calibrated to support the “strategic pivot” to orphan diseases. The integration of these ensures that any data generated from the upcoming Phase 2 proof-of-concept study for TSC-related epilepsy be born from a compliance infrastructure that prioritizes regulatory traceability over narrative convenience.

2027 Solvency Models: Capital Requirement Projections

By February 28, 2026, the arithmetic of Cassava Sciences’ survival has shifted from clinical speculation to rigid actuarial reality. Following the dismissal of the Department of Justice investigation and the execution of the $31. 25 million securities class action settlement in January 2026, the company’s balance sheet has been cleansed of its most volatile liabilities. yet, this legal clarity has come at a catastrophic cost to liquidity. The solvency models for 2027 indicate a binary outcome: the company must execute a highly dilutive capital raise by the fourth quarter of 2026, or face operational insolvency within the quarter of 2027.

The 2026 Starting Line: Post-Settlement Liquidity

To understand the 2027 cliff, one must audit the cash position as of Q1 2026. Cassava Sciences exited 2025 with an estimated cash balance of approximately $94 million, following the aggressive wind-down of the Simufilam Alzheimer’s program. This reserve, while seemingly substantial for a preclinical or early-stage biotech, was immediately depleted by the finalized securities class action settlement.

The $31. 25 million payment, transferred to the settlement escrow in January 2026, reduced the company’s operating capital to approximately $62. 75 million before a single operational check was written for the new fiscal year. Unlike the $40 million SEC penalty paid in late 2024, which was absorbed while the stock still held speculative value, this 2026 outflow occurs in a vacuum of investor confidence, with no Phase 3 catalysts to buoy the share price.

Financial Reality Check: The payment of $31. 25 million represented 33% of the company’s total remaining liquidity. This single transaction accelerated the insolvency timeline by approximately three quarters.

Operational Burn Rate: The TSC Pivot Economics

The pivot to Tuberous Sclerosis Complex (TSC) alters the burn rate profile significantly, not enough to the gap to 2028 without funding. The cost structure of a Phase 2 orphan drug trial differs fundamentally from the global Phase 3 Alzheimer’s Cassava dismantled in 2025.

Projected Quarterly Burn (2026):

• R&D Expenses: Estimated at $4. 5 million to $6. 0 million per quarter. This covers the initiation of the Phase 2 Proof-of-Concept (PoC) study for TSC, including site activation fees, patient recruitment for a rare disease population, and CRO retainers. While significantly lower than the $20 million quarterly burn of the AD program, orphan drug trials carry higher per-patient costs due to recruitment complexity.
• G&A Expenses: Estimated at $6. 5 million to $8. 0 million per quarter. even with workforce reductions, Cassava retains the fixed costs of a public reporting entity, including D&O insurance premiums (which remain elevated due to the company’s litigation history), legal counsel for ongoing derivative matters, and compliance overhead mandated by the SEC settlement’s remedial measures.
• Total Quarterly Cash Burn: $11. 0 million to $14. 0 million.

At this burn rate, the $62. 75 million starting balance (post-settlement) provides a runway of approximately 4. 5 to 5. 5 quarters. This trajectory places the “cash-out” date between March and June 2027.

2026-2027 Cash Flow Projection Model

The following table outlines the base-case liquidity scenario, assuming no new capital inflows and strict adherence to the TSC development timeline.

The Capital Raise Conundrum: Dilution Scenarios

To survive 2027, Cassava Sciences must raise capital before its cash balance drops the $20 million threshold, likely in Q3 2026. yet, the company’s ability to raise funds is severely constrained by its depressed market capitalization following the AD program collapse.

Unlike in 2021, when the company raised over $200 million at share prices exceeding $40, a 2026 capital raise would occur at a valuation fraction of its peak. To secure $50 million, the minimum required to fund the TSC program through Phase 2 readout, the dilution impact would be severe.

• Scenario A (Stock Price $2. 50): Raising $50 million would require the issuance of 20 million new shares. If the outstanding share count is approximately 48 million (as of late 2025), this represents a 41% dilution to existing shareholders.
• Scenario B (Stock Price $1. 50): If the stock drifts lower due to absence of news flow, raising $50 million would require 33. 3 million new shares, a 69% dilution event.

This “death spiral” financing risk creates a feedback loop: the market anticipates the dilution, selling the stock down, which in turn makes the necessary capital raise more dilutive.

Contingent Liabilities and the Yale Agreement

The solvency model must also account for the economic terms of the Yale University license agreement signed in February 2025. While the upfront payment was nominal relative to the company’s cash pile at the time, the agreement includes milestone payments triggered by clinical advancement. The initiation of the Phase 2 TSC trial in 2026 may trigger a milestone payment to Yale, further pressuring the Q2/Q3 2026 cash balance. also, the company is responsible for all patent prosecution and maintenance costs, which for a global patent estate can run between $500, 000 and $1 million annually.

The “Going Concern” Warning

Based on these projections, it is a near certainty that Cassava Sciences’ auditors include a “going concern” qualification in the 2026 Annual Report (filed early 2027) if new capital is not secured by December 31, 2026. This qualification frequently triggers default clauses in vendor contracts and makes securing debt financing impossible. Therefore, the management team is on a six-month clock to execute a strategic transaction or equity sale between March and September 2026.

Conclusion: The 2027 Outlook

The dismissal of the DOJ investigation removed the threat of criminal liability, it did not solve the company’s fundamental solvency emergency. The 2027 outlook is defined by a capital shortfall of approximately $35 million to $50 million needed to complete the TSC Proof-of-Concept trial. Without a non-dilutive partnership or a massive equity sale in 2026, Cassava Sciences exhaust its financial resources in the quarter of 2027. The company has successfully navigated the legal storm, it has emerged into a financial desert.